Category: Now Calling

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

As wild fish stocks decline and fishing regulations tighten, RAS aquaculture is emerging as a global solution for a sustainable seafood supply. RAS—Recirculating Aquaculture Systems—are land-based fish farming systems that enable high-density production, a high level of operational control, and minimal water discharge. 

ART (Aqua-Ring Technology) introduces an advanced system that takes RAS to the next level. ART delivers lower setup costs, reduced energy consumption, a more sterile production environment, and improved fish health—for both hatcheries and grow-out operations.

Unlike most RAS solutions that rely on centralized filtration for the entire farm, ART deploys dedicated filters for each individual fish tank. This design isolates disease events to a single tank, preventing farm-wide contamination through shared filters.

Independent filtration also enables true modularity. Farmers no longer need to invest heavily upfront to build a full-scale facility. With ART, farms can be expanded incrementally, scaling up only after gaining operational experience and confidence.

Another key feature of Art is limiting stocking density to 25 kg per cubic meter. This minimizes energy consumption, and stress on equipment—thereby decreases maintenance expenses.

In addition, medium stocking density improves fish welfare compared to high-density systems. This is aligned with the latest regulatory trends regarding RAS aquaculture.

Finally—medium stocking density combined with the Art architecture, enables the farming of a wide range of species, including shrimp and marine fish. Art makes it possible to produce species that are difficult to source fresh, get premium prices, and expand consumer access to diverse, high-quality seafood.

The bottom line: with tank-dedicated filtration and medium stocking densities that enhance fish health, farmers benefit from lower capital and operating costs, greater system stability, and reduced risk. At the same time, markets gain consistent, year-round access to a broader variety of fresh fish and shrimp—independent of seasonality or weather.

Art is now seeking pilot sites across multiple geographies and species. Join us in taking RAS aquaculture to its next level. Join us!

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

Molecular separation and protein purification can be costly and pose challenges to contemporary production lines. This new technology reduces the cost of these processes, and makes it more scalable and environmentally friendly. The company is now seeking partners for the EIT program.

Various industrial processes require molecular separation or protein purification. However, this stage is often expensive or technically challenging. Below are the methods currently used for separation or purification, along with the challenges faced across industries:

• • Chromatography/resins – While selective and precise, electrical charge-based separation is typically expensive, often costing more than $1,000 per kilogram. Additionally, the production of synthetic resins from crude oil poses significant environmental challenges.
  • Ultra/nano filtration systems require multiple stages and often face the challenge of frequent filter blockages or clogs.
  • Dialysis is a slow process that requires large amounts of water and poses challenges to scalability.

Consequently, modern molecular separation and protein purification processes significantly influence downstream costs and pose scalability challenges for the food, beverage, flavor, fragrance, cosmetics, chemical, and pharmaceutical industries.

A new, proprietary technology enables the use of an alternative downstream process that leverages natural separation mechanisms, such as ion exchange and size exclusion. This approach offers the following benefits:

• • It utilizes low-cost biological substances, achieving over 80% cost reduction compared to traditional purification methods, such as synthetic resins.
  • It is more effective than other filtration solutions, providing a scalable alternative for downstream processes.
  • It is environmentally friendly and biodegradable.

These benefits offer manufacturers a valuable opportunity to revolutionize ingredient production on their production lines.

The Company is seeking the following types of collaboration:

• • Ingredient Producers:

Category 1: Protein/enzyme producers using precision fermentation or other production processes. These producers use weak cation-exchange methods to isolate target molecules such as lysozyme, papain, trypsin, peptides, or lactoferrin.

Category 2: Producers aiming to eliminate or isolate small molecules (up to 5 kDa) such as lactate, ammonia, small polyphenols, or coumarin.

• • Potential Distributors:
    Distributors could include bio-process design companies (CDMOs), equipment manufacturers (e.g., fermenters, tanks, columns), or distributors of resins and filtration solutions.

  • Potential Manufacturers (CMOs):
    Manufacturers could be food production or processing facilities, or any company capable of producing biological materials using simple GRAS materials under food regulatory standards. The scope could expand in the future to support additional industries.

Collaboration shall aim at integrating and commercializing the technology within the specific production processes of the selected producer. It will also focus on building the necessary infrastructure to scale up production and facilitate product distribution.

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

This innovative absorption system can produce drinking water in drier climates with greater efficiency and at a lower cost. The company is now seeking strategic partners to scale and implement this breakthrough solution.

1 in 4 people globally lacked secure access to clean drinking water in 2023 (Source: UN). Affected regions include developing nations in Central Africa, East Asia, South America, and the Middle East, as well as major cities in developed countries such as Mexico City, Los Angeles, Phoenix, Dallas, Bucharest, and New Delhi. While concerning, this crisis has also created a significant global demand for off-grid drinking water solutions.

Current, routine solutions include:

• Routine supply of bottled water.
• Air-condensatoin systems, where specific humidity levels exceed 10 gr/kg.

Where humidity levels go below 10 gr/kg, air condensation systems are challenged to produce water from air, and water supply relies on routine, expensive consumption of bottled water. Examples are Mexico, Argentina, Spain, Canada, and various states in the US.

A Breakthrough in Absorption Technology

A new absorption system overcomes the challenge of dry climate conditions, enabling mass water production in such areas with significantly higher efficiency and lower cost, compared to routine supply of bottled water. This is achieved through an innovative technology that separates moisture from bulk air. The system supports continuous water production, rather than batch-mode operation, and without biological, chemical, or physical airborne contaminants.

Partnership Opportunities

The company is actively seeking strategic partners for one or more of the following purposes:

• Further development of large-scale systems to enhance efficiency and reduce costs.
• Strategic pilot programs with urban, governmental, or international organizations.
• Pilot collaborations with potential distribution partners.
• Investment from companies capable of supporting large-scale deployment projects.

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

This new non-cultivation technology has the potential to become a real alternative to standard practices, in a near future. Collaboration opportunities are now being pursued. 

While bovine mastitis is commonly detected through routine lab tests, it is often too late to prevent illness, and a breakout. Such culture-based tests take a few days until the results are available and by that time, an already-existing infection would worsen. In addition, since such tests indicate the somatic cell count (SCC), they would typically yield negative results at the subclinical stage, when SCC is yet to indicate an infection. The probability of getting a false-negative result for such commonly-used lab tests has been estimated at 20-50% (source).

Consequently, mastitis is one of the most significant challenges that dairy farms face worldwide, with considerable economic, operational, and animal welfare implications. Clinical cases would trigger losses of milk production, discarded milk, veterinary expenses, excess labor for monitoring and treatment, and losses due to premature culling. All in all, the cost of clinical mastitis has been estimated at 444 USD per case in the US (source), and 662 CAD per case in Canada (source). These costs, with geographic adjustments, apply to most of dairy farms around the world, as around 20–30% of dairy cows are diagnosed with a mastitis episode, at least once during lactation (source).

A new “lab on chip” (LoC) technology, that can be applied through standard smartphones on-farm – is now offering a quick and handy alternative to the commonly used method of SCC lab testing. This technology involves miniature, optical biosensors that use nanomaterials to detect mastitis pathogens such as e. coli, klebsiella spp, streptococcus uberis, and streptococcus dysgalactiae. Detection is achieved within 60 minutes, for batches of tens of tests, at sensitivity level of 10 CFU/mL, using a standard smartphone camera. No cultivation is required. As such, this technology enables onsite, real time, quick DYI detection of current or even subclinical mastitis, for immediate triggering of treatment or prevention activities.

Future dairy-market regulation around the world is expected to require the usage of on-farm solutions, sooner or later, to better control milk quality, and reduce the wide usage of antibiotics in the dairy industry. However, emerging, other on-farm solutions:

• Typically involve cultivation kits, which may be too cumbersome to use for farmers, and may require investments in dedicated facilities.
• Allow for testing only a few cows per kit – not tens of batches at one shot.
• Allow for getting the results after about a day – not within just one hour.

Therefore, this technology provides the opportunity of getting ahead of regulatory requirements and competition, and leading the market for on-farm microbiological tests.

The Company is now seeking collaboration opportunities for final product development, pilots, and commercialization.

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

Diabetic ulcers are challenging to heal and often lead to hospitalization, limb amputation, and disability. Effective wound healing begins with the crucial first step: debridement, which removes necrotic and infected tissue that hinders recovery.

Several debridement methods are commonly used; however, they are often incomplete, fail to promote healing, and present the following additional challenges:

• Surgical debridement requires specialized skills, is time-consuming, and may necessitate anesthesia.
• Enzymatic debridement is occasionally used after surgery but can cause irritation or allergic reactions.
• Autolytic debridement is a slow process and may not be suitable for infected or heavily necrotic wounds.
• Mechanical debridement, such as wet-to-dry dressings, can adhere to healthy tissue, potentially causing additional pain, trauma, and an increased risk of infection when removed.
• Antibiotics often lead to the emergence of drug-resistant bacteria load.
• Antiseptics may cause irritation, pain, allergic reactions, and may be cytotoxic to healthy cells.

An innovative, antiseptic, non-toxic irrigation product has recently been proven to deliver effective and rapid debridement, overcoming the challenges associated with current methods:

• Debridement Activity: The product penetrates and lifts biofilms and dead tissue, revealing healthy epithelium, which supports tissue regeneration.
• No Drug Resistance: This product does not contribute to the emergence of drug-resistant bacteria.
• Constant Irrigation: The product provides continuous irrigation of the wound by spraying the solution onto the bandage or dressing, helping to maintain a moist environment. This process keeps the lesion sanitized, actively debrides the wound, and promotes the development of healthy granulation tissue. The moisture also aids the body’s enzymes, neutrophils, growth factors, and macrophages in digesting and liquefying the necrotic tissue.
• Tissue Compatibility: The solution obtained from dissolving the product contains 1000 ppm (parts per million) of Latent Available Chlorine and has a pH range of 5 to 6.2. This pH level is neutral for healthy tissue, meaning it does not cause irritation, pain, or damage to new granulation tissue or other healthy cells.
• Versatility: The product can be used for all types of wounds, including diabetic ulcers, pressure sores, infected wounds, and other injuries. It promotes rapid wound healing and closure.
• Hygiene: The product’s high cleansing effectiveness has been shown to significantly reduce wound contamination.
• Ease of Use: Designed for home use, this product is easy to apply. Simply dissolve it in water and spray it onto the bandage or dressing throughout the day.

The product is already registered and is widely used by HMOs in one region. The company is now seeking collaboration with distributors to support further clinical trials, regulatory processes, and the expansion of distribution into new regions.

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

A leading textile manufacturer is now seeking innovative solutions for the textile industry. Access to leading fashion houses may be facilitated.

Relevant solutions may involve various processes across textile related processes, production to distributions, such as:

• Innovative types of fabric
• New tools for generating new designs
• New tools for facilitation of efficient cutting
• New tools for reducing manual handling during production
• New solutions for expediting low-volume production cycles
• New tools for advancing online sales

The Company manufactures various types of garments in several geographies, at highest quality. As such it can provide professional support by highly experienced staff, serve as a think tank for considering variuos options of integration and commercialization, advise about financial aspects, and tailore win-win mechanisms.

If your solution may revolutionize the textile industry – it may suit the level of impact pursued. 

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

 

An innovative iodine-free product now enables dairy farms to reduce somatic cell count (SCC) quickly, effectively, and at a lower cost, without the use of iodine. The Company is now seeking distributors in additional geographies. 

Mastitis, a bacterial infection and a persistent health issue in dairy herds, negatively impacts milk production, animal health, and the overall economy of the dairy industry.

Improved hygiene practices make it possible to shift from blanket dry cow treatment (BDCT) to selective dry cow treatment (SDCT), reducing the need for antibiotics. Most commonly used hygiene products are iodine-based, which is expensive and poses risks to farm workers, animals, and consumers, as iodine residues can be transferred into the milk.

An innovative chlorine-based product now enables dairy farms to maintain hygiene and more effectively reduce somatic cell count (SCC) in milk—without using toxic products and at a lower cost. It also offers several key advantages:

• Covers a broader range of bacteria, fungi, and spores compared to other products based on chlorine, iodine, or lactic acid, allowing for an effective and consistent protocol to prevent infections.
• Unlike other chlorine-based products, it does not contain hypochlorite, which rapidly disintegrates into gas and produces unwanted byproducts.
• Includes a colored dye to highlight treated areas, making it easier to identify any untreated areas of the udder.
• Easy to prepare by simply adding water. The product comes in effervescent tablet form, which self-dissolves in tap water. Its dry format reduces transportation costs and improves logistical efficiency.
• Has a neutral pH, proven to be safe for both cows and farm workers.

The following chart illustrates the product’s efficacy in one of many experiments already conducted:

The company is now seeking pilot opportunities in additional regions to demonstrate product performance, secure local regulatory approval, and establish partnerships with potential distributors.